The CHARM study was supported by Abbott Laboratories, Abbott Park, IL. Financial disclosures: W.J.S. served as study investigator and consultant for Abbott Laboratories and has participated in continuing medical education events supported by unrestricted educational grants from Abbott; received research support and consultant fees from Centocor, Inc., Elan Pharmaceuticals, Schering-Plough, and UCB. J.F.C. received consulting fees and research support from Abbott. S.S. served as study investigator and consultant for Abbott and has participated in continuing medical education events supported by unrestricted educational grants from Abbott; and served as consultant for Centocor, Inc., Schering-Plough, and UCB. S.E.P. received research support from Abbott and Centocor, Inc.; consulting fees from Abbott, Centocor, Inc., Elan Pharmaceuticals, Johnson & Johnson, Schering-Plough, and UCB; and honoraria (speaker) from Abbott, Centocor, Inc., Elan Pharmaceuticals, Mitsubishi Tanabe, and UCB. P.F.P., A.M.R., J.C., and P.M. are employees of Abbott Laboratories.
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics†
Article first published online: 10 MAY 2010
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 1, pages 141–151, January 2011
How to Cite
Sandborn, W. J., Colombel, J.-F., Schreiber, S., Plevy, S. E., Pollack, P. F., Robinson, A. M., Chao, J. and Mulani, P. (2011), Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis, 17: 141–151. doi: 10.1002/ibd.21328
- Issue published online: 8 DEC 2010
- Article first published online: 10 MAY 2010
- Manuscript Accepted: 17 MAR 2010
- Manuscript Received: 23 FEB 2010
- 17Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn's disease. Manag Care Interface. 2008; 21: 20–23., , , et al.
- 18An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 1984–1989., , , et al.Direct Link:
- 21Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States. J Crohns Colitis. 2009; 3: S7., , , et al.
- 22HUMIRA [summary of product characteristics]. Kent, UK: Abbott Laboratories. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/humira/emea-combined-h481en.pdf Accessed February 15, 2010.
- 23HUMIRA [prescribing information]. North Chicago, IL: Abbott Laboratories; 2010.
- 26Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology. 2007; 132( 4 Suppl 1): A505., , , et al.
- 27Regain of response and remission by dose adjustment in patients with Crohn's disease who responded to certolizumab pegol: results from the WELCOME study. Am J Gastroenterol. 2009; 104( Suppl 3): S450–S451., , , et al.
- 28WELCOME: a randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab. Gastroenterology. 2009; 136( 5 Suppl 1): A-27., , , et al.